6-K

FORM 6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the Month of April, 2024

Commission File Number 0-51504

GENETIC TECHNOLOGIES LIMITED

(Exact Name as Specified in its Charter)

N/A

(Translation of Registrant’s Name)

60-66 Hanover Street

Fitzroy

Victoria 3065 Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐ 

This Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant’s Registration Statement on Form F-3 (File Nos. 333-276168), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit Index

Exhibit No.	Description
99.1	Cleansing Notice under section 708A of the Corporations Act 2001 (Cth)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: April 23, 2024

GENETIC TECHNOLOGIES LIMITED
By:	/s/ Kathryn Andrews
Name:	Kathryn Andrews
Title:	Company Secretary

EX-99.1

Exhibit 99.1

22 April 2024

Company Announcements Office

ASX Limited

Dear Sir/Madam

Genetic Technologies Limited

Cleansing Notice under section 708A of the Corporations Act 2001 (Cth)

On 19 April 2024 Genetic Technologies Limited ACN 009 212 328 (ASX: GTG; NASDAQ: GENE) (the Company) announced that it had received commitments for an aggregate of US$2 million (before expenses and costs of the issue) via a private placement of 30,000,000 fully paid ordinary shares (Shares) in the Company (represented by 1,000,000 American depositary shares (ADSs) or ADS equivalents in lieu thereof in the nature of pre-funded warrants), of the Company) to various US sophisticated and institutional investors introduced by HCW Wainwright & Co at an issue price of US$2.00 per ADS or the equivalent of A$0.10 per Share (Placement).

The Company gives this cleansing notice (Notice) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act). The Placement Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.

As at the date of this Notice, the Company has complied with:

● the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

● section 674 of the Corporations Act.

As at the date of this Notice, there is no excluded information for the purposes of section 708A(7) and section 708A(8) of the Corporations Act.

Yours faithfully

Kathryn Andrews

CFO and Company Secretary

Genetic Technologies Limited

Genetic Technologies Limited www.genetype.com info@gtglabs.com ABN 17 009 212 328 60-66 Hanover Street Fitzroy Victoria 3065 Australia +61 3 8412 7000